{"id":"alkalinized-lidocaine-heparin","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"3%","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Lidocaine is a local anesthetic that blocks sodium channels, preventing the initiation and transmission of nerve impulses. Heparin is an anticoagulant that inhibits thrombin and factor Xa, preventing blood clot formation.","oneSentence":"Lidocaine inhibits sodium channels, while heparin inhibits coagulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:21:01.630Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardioversion, defibrillation, and local anesthesia"}]},"trialDetails":[{"nctId":"NCT06394830","phase":"PHASE2","title":"Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS)","status":"RECRUITING","sponsor":"Vaneltix Pharma, Inc.","startDate":"2024-12-13","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":50},{"nctId":"NCT05737121","phase":"PHASE2","title":"Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS","status":"RECRUITING","sponsor":"Vaneltix Pharma, Inc.","startDate":"2023-05-22","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":120},{"nctId":"NCT05414305","phase":"PHASE2","title":"The Female Microbiome in Patients Undergoing Bladder Instillation Therapy","status":"COMPLETED","sponsor":"Walter Reed National Military Medical Center","startDate":"2020-10-01","conditions":"Interstitial Cystitis, Bladder Pain Syndrome, Microbial Colonization","enrollment":29},{"nctId":"NCT04401176","phase":"PHASE2","title":"Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome","status":"COMPLETED","sponsor":"Walter Reed National Military Medical Center","startDate":"2020-09-15","conditions":"Interstitial Cystitis, Bladder Pain Syndrome","enrollment":58},{"nctId":"NCT00256542","phase":"PHASE2","title":"Study of U101 for Bladder Pain and/or Urgency","status":"COMPLETED","sponsor":"Urigen","startDate":"2006-01","conditions":"Pelvic Pain, Interstitial Cystitis, Bladder Diseases","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Alkalinized Lidocaine-Heparin","genericName":"Alkalinized Lidocaine-Heparin","companyName":"Urigen","companyId":"urigen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lidocaine inhibits sodium channels, while heparin inhibits coagulation. Used for Cardioversion, defibrillation, and local anesthesia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}